Investigating the correlation of hip circumference to cardiovascular disease and type-2 diabetes using Mendelian
Hongtao Liu1, Zhaoyu Li2, Su Yan2
1Guangxi Health Science College, Nanning, China.
Insights
Hip circumference (HC) is causally linked to cardiovascular disease (CVD) and type 2 diabetes mellitus risk. After adjusting for body mass index (BMI), increased hip fat offers protection against type 2 diabetes mellitus but not CVD.
Area of Science:
- Genetics
- Metabolic Diseases
- Cardiovascular Health
Background:
- Observational studies suggest associations between hip circumference (HC) and cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM).
- Mendelian randomization (MR) can overcome limitations of observational studies by using genetic variants as instrumental variables.
Purpose of the Study:
- To assess the causal relationship between hip circumference (HC) and the risk of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM).
- To investigate whether these relationships are independent of body mass index (BMI).
Main Methods:
- Two-sample Mendelian randomization (MR) analysis using genetic variation data from MR Base.
- Employed MR-Egger regression, weighted median estimator, and inverse variance weighting (IVW) methods.
- Utilized summary statistics from genome-wide association studies (GWAS) for HC (adjusted and unadjusted for BMI) as exposures and CVD and T2DM as outcomes.
Main Results:
- Unadjusted HC showed a positive causal association with both CVD and T2DM.
- After adjusting for BMI, HC was not significantly associated with CVD.
- BMI-adjusted HC exhibited a negative causal association with T2DM, suggesting a protective effect.
Conclusions:
- Adipose tissue distribution, specifically hip circumference, plays a differential role in metabolic and cardiovascular health.
- Increased hip fat, after accounting for overall adiposity (BMI), appears protective against type 2 diabetes mellitus.
- Findings suggest potential implications for T2DM prevention and treatment strategies, and warrant further investigation into underlying mechanisms.
Objective:
This study aimed to assess the correlation between hip circumference (HC) and the risk of cardiovascular disease (CVD) and type 2 diabetes mellitus using Mendelian randomization (MR) to overcome observational study limitations.
Design:
MR analysis utilized genetic variation from the MR Base in a two-sample analysis. Three methods were employed: MR-Egger regression, weighted median estimator, and inverse variance weighting (IVW).
Setting:
Data was acquired from MR Base, a platform summarizing genome-wide association study (GWAS) data for MR research.
Main Outcome Measures:
Publicly available summary statistics datasets from GWAS meta-analyses were used, with HC and HC adjusted for body mass index (BMI) as exposures. Data for CVD and type 2 diabetes mellitus were obtained as outcomes.
Results:
Results indicated a positive causal relationship between HC and CVD (IVW: P = 1.84e-07, OR: 1.37, 95% CI: 1.22-1.54) as well as type 2 diabetes mellitus (IVW: P = 0.04, OR: 1.62, 95% CI: 1.02-2.56), independent of BMI. However, HC after BMI adjustment showed no significant causal relationship with CVD (IVW: P = 0.05, OR: 1.09, 95% CI: 1.00-1.19) and exhibited a negative association with type 2 diabetes mellitus (IVW: P = 0.00, OR: 0.76, 95% CI: 0.66-0.88), suggesting a protective effect against type 2 diabetes mellitus.
Conclusions:
After adjusting for BMI, adipose tissue concentrated in the hip region showed a protective effect against type 2 diabetes mellitus but not against CVD. These findings offer insights into diabetes prevention and treatment strategies, and may inform plastic surgery procedures. Further research is needed to validate these findings and explore underlying mechanisms.
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Bias in Epidemiological Studies
Confounding in Epidemiological Studies
Cholesterol: Significance and Regulation
Considering cholesterol and...
Hazard Ratio
For example, in a clinical trial...


